NCT06767462

An Ophthalmic Safety Study in Patients With Breast Cancer

A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 160 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Detailed description

This is a multicentre study assessing the ophthalmic safety in patients who are participating in a qualifying study. The study will include two cohorts of at least 60 individuals each. To be able to account for events associated with aging, worsening of pre-existing conditions, etc., ophthalmic study assessments will be performed in parallel in two cohorts at the same timepoints. The duration of the study assessment period will be approximately 12 months. Longer duration of the study would result in additional patient burden.

Conditions

• Ophthalmic Safety in Patients With Breast Cancer

Timeline

• Start date: 2025-03-04
• Primary completion: 2027-07-06
• Completion: 2027-07-06
• First posted: 2025-01-10
• Last updated: 2025-07-23

Locations

75 sites across 14 countries: United States, Argentina, Belgium, Brazil, Canada, Chile, France, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain